Personalised medicine for nonsmall cell lung cancer

被引：34
|
作者：
Mascaux, Celine [1 ,2 ]
Tomasini, Pascale [1 ,2 ]
Greillier, Laurent [1 ,2 ]
Barlesi, Fabrice [1 ,2 ]
机构：
[1] Aix Marseille Univ, AP HM, Multidisciplinary Oncol & Therapeut Innovat Dept, Marseille, France
[2] Aix Marseille Univ, Inserm U911 CRO2, Marseille, France
来源：
EUROPEAN RESPIRATORY REVIEW | 2017年 / 26卷 / 146期
关键词：
PHASE-III TRIAL; CISPLATIN PLUS GEMCITABINE; OPEN-LABEL; 1ST-LINE TREATMENT; DOUBLE-BLIND; PD-L1; IMMUNOHISTOCHEMISTRY; MAINTENANCE THERAPY; MET AMPLIFICATION; AMERICAN-SOCIETY; PEMETREXED PLUS;
D O I：
10.1183/16000617.0066-2017
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer.
引用
收藏
页数：13
相关论文
共 50 条
  • [1] Nonsmall cell lung cancer
    Sculier, Jean-Paul
    EUROPEAN RESPIRATORY REVIEW, 2013, 22 (127): : 33 - 36
  • [2] Treatment of advanced nonsmall cell lung cancer in the era of precision medicine
    Yang, James Chih-Hsin
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Update on nonsmall cell lung cancer
    Zalcman, G.
    Bergot, E.
    Lechapt, E.
    EUROPEAN RESPIRATORY REVIEW, 2010, 19 (117): : 173 - 185
  • [4] Surgery for nonsmall cell lung cancer
    Lang-Lazdunski, Loic
    EUROPEAN RESPIRATORY REVIEW, 2013, 22 (129): : 382 - 404
  • [5] The Possibility of Traditional Chinese Medicine as Maintenance Therapy for Advanced Nonsmall Cell Lung Cancer
    Xu, Weiru
    Yang, Guowang
    Xu, Yongmei
    Zhang, Qing
    Fu, Qi
    Yu, Jie
    Yu, Mingwei
    Zhao, Wenshuo
    Yang, Zhong
    Hu, Fengshan
    Han, Dong
    Wang, Xiaomin
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014
  • [6] Troxacitabine prodrugs for nonsmall cell lung cancer
    Chu, Chung K.
    Radi, M.
    Adema, A. D.
    Hoebe, E. K.
    Alexander, L. M. M.
    Peters, G. J.
    CANCER RESEARCH, 2006, 66 (08)
  • [7] Modern therapies of nonsmall cell lung cancer
    Andrzej Jachowski
    Mikołaj Marcinkowski
    Jakub Szydłowski
    Oskar Grabarczyk
    Zuzanna Nogaj
    Łaz Marcin
    Andrzej Pławski
    Paweł Piotr Jagodziński
    Bartosz Kazimierz Słowikowski
    Journal of Applied Genetics, 2023, 64 : 695 - 711
  • [8] ALK Inhibitors in Nonsmall Cell Lung Cancer
    Garg, Nitish
    Kothari, Rushabh
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (01) : 67 - 70
  • [9] DNA Methylation and Nonsmall Cell Lung Cancer
    Lu, Fang
    Zhang, Hong-Tao
    ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY, 2011, 294 (11): : 1787 - 1795
  • [10] THERAPY OF NONSMALL CELL LUNG-CANCER
    KLASTERSKY, J
    LUNG CANCER, 1995, 12 : S133 - S145
12345